Alyeska Investment Group L.P. Has $7.97 Million Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Alyeska Investment Group L.P. increased its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 52.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,808,514 shares of the company's stock after buying an additional 3,041,058 shares during the period. Alyeska Investment Group L.P. owned 3.89% of Gossamer Bio worth $7,968,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after purchasing an additional 13,902 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after buying an additional 1,520,721 shares in the last quarter. Geode Capital Management LLC boosted its position in Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after buying an additional 38,084 shares during the last quarter. Smith Moore & CO. raised its position in shares of Gossamer Bio by 32.7% during the fourth quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock worth $271,000 after acquiring an additional 74,000 shares during the last quarter. Finally, Silverarc Capital Management LLC lifted its stake in shares of Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after acquiring an additional 526,495 shares during the period. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Trading Down 0.9 %

Shares of GOSS stock traded down $0.01 on Friday, reaching $1.11. The company had a trading volume of 998,296 shares, compared to its average volume of 1,535,986. The stock has a market cap of $252.22 million, a PE ratio of -3.47 and a beta of 1.82. The company has a 50-day moving average of $1.06 and a 200-day moving average of $0.99. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million. On average, equities analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. The Goldman Sachs Group dropped their price objective on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a report on Thursday, April 17th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.